InMed Pharmaceuticals (INM) EBITDA (2021 - 2026)

InMed Pharmaceuticals' EBITDA history runs 6 years deep, the most recent figure standing at -$2.4 million for Q1 2026.

• On a quarterly basis, EBITDA fell 23.64% year-over-year to -$2.4 million in Q1 2026; TTM through Mar 2026 was -$8.8 million, a 10.33% decrease from a year earlier, with the FY2025 full-year figure at -$7.9 million, up 3.05% from the prior year.
• EBITDA declined to -$2.4 million in Q1 2026 per INM's latest filing, from -$2.1 million in the prior quarter.
• Across five years, EBITDA topped out at -$485150.0 in Q2 2023 and bottomed at -$6.5 million in Q2 2022.
• The 5-year median for EBITDA is -$2.2 million (2023), against an average of -$2.4 million.
• Across the five-year window, EBITDA surged 92.56% in 2023 and slumped 319.3% in 2024, its largest moves.
• Year by year, EBITDA stood at -$2.2 million in 2022, then rose by 25.7% to -$1.6 million in 2023, then sank by 37.03% to -$2.3 million in 2024, then increased by 6.72% to -$2.1 million in 2025, then declined by 12.19% to -$2.4 million in 2026.
• Per Business Quant, the three latest INM EBITDA figures stand at -$2.4 million (Q1 2026), -$2.1 million (Q4 2025), and -$1.8 million (Q3 2025).